BCR-ABL tyrosine kinase inhibitor: Class Overview and Comparison
Quick answer: BCR-ABL tyrosine kinase inhibitor are a class of medicines used for specific therapeutic indications. iMedic covers 7 bcr-abl tyrosine kinase inhibitor substances. Below is a comparison table linking to detailed pages for each.
BCR-ABL tyrosine kinase inhibitor on iMedic (7 substances)
| Substance | Primary indications | Mechanism | Common dose |
|---|---|---|---|
| Bosulif | Chronic myeloid leukemia | Brand name for bosutinib; inhibits BCR-ABL and Src-family kinases | 400-500 mg once daily |
| Bosutinib | Chronic myeloid leukemia (Philadelphia chromosome positive) | Dual SRC/ABL tyrosine kinase inhibitor blocking BCR-ABL signaling in CML | 400-500 mg once daily |
| Dasatinib | Chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia | Inhibits BCR-ABL and SRC family kinases, blocking proliferation of Philadelphia | 100-140 mg once daily |
| Dasatinib Accord Healthcare | Chronic myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia | Inhibits BCR-ABL and SRC family kinases, blocking proliferation of Philadelphia | 100-140 mg once daily |
| Imatinib | Chronic myeloid leukemia, Gastrointestinal stromal tumor | Selective inhibitor of BCR-ABL, KIT, and PDGFR tyrosine kinases blocking prolife | 400-800 mg orally once daily |
| Nilotinib | Chronic myeloid leukemia (CML), Philadelphia chromosome-positive leukemia | Selective BCR-ABL tyrosine kinase inhibitor blocking proliferation of Ph+ leukem | 300-400 mg twice daily |
| Tasigna | Chronic myeloid leukemia (Philadelphia chromosome-positive) | Selectively inhibits BCR-ABL tyrosine kinase activity, blocking proliferation of | 300-400 mg twice daily |
About BCR-ABL tyrosine kinase inhibitor
BCR-ABL tyrosine kinase inhibitor share a common mechanism of action and clinical use. Specific dosing, side effects, contraindications, and drug interactions vary between individual substances within the class. Click any substance above for full prescribing information and patient guidance.
Common considerations across the class
- Indication-specific selection: Different members may be preferred for different conditions or patient populations
- Dose equivalence: Members of the same class are not always interchangeable on a 1:1 dose basis
- Drug interactions: Class members often share interaction profiles (e.g., CYP enzyme effects) but individual variation matters
- Side effects: Some side effects are class-wide; others are substance-specific
- Contraindications: Individual contraindications may not generalize across the class
Always consult the prescribing information for the specific medicine prescribed and discuss with your clinician.
Frequently asked questions
What are BCR-ABL tyrosine kinase inhibitor?
BCR-ABL tyrosine kinase inhibitor are medicines that share a common mechanism of action used for specific therapeutic indications. iMedic currently covers 7 substances in this class with detailed pages for each.
Are all BCR-ABL tyrosine kinase inhibitor interchangeable?
No. While medicines in the same class share a mechanism, they differ in potency, dosing, drug interactions, and tolerability. Switching between them is a clinical decision based on individual response, side effects, and treatment goals.
How do I choose between different BCR-ABL tyrosine kinase inhibitor?
Selection depends on the specific clinical indication, patient factors (age, comorbidities, kidney/liver function, other medications), tolerability of side effects, cost, and clinician preference. This is a prescribing decision.
Are BCR-ABL tyrosine kinase inhibitor available as generics?
Most well-established class members are available as generic alternatives, often substantially less expensive than brand-name versions while clinically equivalent. Newer members may still be brand-only.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.